Aptorum Group is now the first biopharmaceutical company listed on the Nasdaq to be admitted to Euronext, with shares trading from 24 July 2020.
The Reed Smith team that advised on the listing was led by Paris based partner Guilain Hippolyte and associate Lucie Guegan. They were supported by London based partner James Wilkinson and associate Fiona McFarlane, and New York based partner Gerry DiFiore and associate Sheran Sharafi.
Hippolyte said: “We are proud to have supported Aptorum Group on its listing on Euronext Paris, which is an important milestone following its successful listing on the Nasdaq. The listing underlines our Global Corporate Group’s in depth understanding of the life sciences industry, particularly in cross-border operations requiring international coordination.”
During the Euronext admission ceremony, Darren Lui, Chairman and CEO of Aptorum Group, said: “Europe is a key market for our future developments. I am convinced that the listing of our group on both stock exchanges will further diversify our investor base as well as strengthening the company's global recognition. It will also help us expand our presence in Europe and provide us with new business opportunities to engage in research and development projects. "
About Reed Smith
Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. Our belief is that by delivering smarter and more creative legal services, we will not only enrich our clients’ experiences with us, but also support them in achieving their business goals.
Our long-standing relationships, international outlook, and collaborative structure make us the go-to partner for the speedy resolution of complex disputes, transactions, and regulatory matters.
For further information, please visit reedsmith.com.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle current unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women’s health supplement, dioscorea opposita bioactive nutraceutical tablets marketed under the brand name NativusWell®.
For more information about Aptorum Group, please visit our website: www.aptorumgroup.com.
